Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Touyun Biotech Group Limited

透雲生物科技集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 1332)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2025

Reference is made to the annual report of Touyun Biotech Group Limited (the "**Company**") for the year ended 31 December 2025 published on 22 April 2026 (the "**2025 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2025 Annual Report. This announcement provides supplemental information to the 2025 Annual Report and should be read in conjunction with the 2025 Annual Report.

SHARE OPTION SCHEME

In addition to the information provided in the 2025 Annual Report, the Company wishes to provide to the shareholders and potential investors of the Company with the following additional information in relation to the share option scheme adopted on 13 June 2025 (the "**2025 Scheme**") pursuant to the Rule 17.09 of the Listing Rules.

(i) The participants of the scheme

Eligible participants of the 2025 Scheme include (a) the Employee Participant(s); (b) the Related Entity Participant(s); and (c) Service Provider(s).

"The Employee Participant(s)" means director(s) and employee(s) (whether full-time or part-time but excludes a former employee of the Group) of any member of the Group (including persons who are granted Options under the 2025 Scheme as inducement to enter into employment contracts with any member of the Group).

"The Related Entity Participant(s)" means directors and employees (whether full-time or part-time but excludes any former employee) of the holding companies, fellow subsidiaries or associated companies of the Company.

"The Service Provider(s)" means any person (natural person or corporate entity) who provides services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, person(s) who work(s) for the Company as (i) independent contractors; (ii) independent suppliers; and (iii) advisers or consultants, but excluding any placing agents or financial advisors providing advisory services for fundraising, mergers or acquisitions, and professional service providers such as auditors or valuers who provide assurance, or are required to perform their services with impartiality and objectivity, and provided that the Board shall have absolute discretion to determine whether or not one falls within such category.

(ii) The vesting period of options granted under the scheme

An option must be held by the grantee for at least twelve (12) months (the "**Vesting Period**") before the option can be exercised.

(iii) The basis of determining the exercise price of options granted

The exercise price of an option is determined at, which is higher than the highest of: (a) the closing price per share as quoted on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") on the date of grant; (b) the average closing price per share as quoted on the Stock Exchange for the 5 consecutive trading days immediately preceding the date of grant; and (c) the nominal value of a share of the Company.

(iv) The remaining life of the scheme

Subject to any early termination determined by the Board in accordance with the terms of the 2025 Scheme, the 2025 Scheme is valid and effective for a term of 10 years commencing on its adoption date (i.e. 13 June 2025). Accordingly, the 2025 Scheme will be expired on 13 June 2035.

The Company by an ordinary resolution in general meeting may at any time terminate the operation of the 2025 Scheme and in such event no further options will be offered but in all other respects the provisions of the 2025 Scheme shall remain in force to the extent necessary to give effect to the exercise of any options granted but not yet exercised prior thereto or otherwise as may be required in accordance with the provisions of the 2025 Scheme and options granted prior to such termination shall continue to be valid and exercisable in accordance with the 2025 Scheme.

SECURITIES INVESTMENTS

As at 31 December 2025, the Group held listed equity investments and unlisted equity investments of approximately HK$97.8 million and HK$181.2 million respectively, as disclosed in the 2025 Annual Report.

The details of investment portfolio as at 31 December 2025 is set out below:

Category	**Investment type**	**Investment strategy**	**Investment period**	**Source of Funding**	**Fair value** *HK$' million*	**Performance for FY2025**
Financial assets at fair value through profit or loss	Listed equity investments	Bottom-up fundamental analysis and top-down market data assessment	Medium to long term	Internal resources of the Group	97.8	Increase of approximately HK$46.6 million, mainly due to increase in share price of the listed equity securities
Financial assets at fair value through profit or loss	Unlisted equity investments	Strategic minority holding in the investee to diversify the investment portfolio and retained for its long-term value	Long term	Internal resources of the Group	181.2	Increase of approximately HK$85.3 million, mainly due to reflecting the improved financial performance of the investee; and acquisition of new unlisted equity investments in 2025

The above additional information does not affect other information contained in the 2025 Annual Report. Save as disclosed above, all other information in the 2025 Annual Report remains unchanged.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 17 November 2026

As at the date of this announcement, the Board comprises the following directors:

Executive Directors
Mr. Wang Liang *(Chairman)*
Ms. Zhou Ruijuan *(Vice chairlady)*
Mr. Du Dong

Non-executive Directors
Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors
Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen